IL206484A0 - Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene - Google Patents

Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene

Info

Publication number
IL206484A0
IL206484A0 IL206484A IL20648410A IL206484A0 IL 206484 A0 IL206484 A0 IL 206484A0 IL 206484 A IL206484 A IL 206484A IL 20648410 A IL20648410 A IL 20648410A IL 206484 A0 IL206484 A0 IL 206484A0
Authority
IL
Israel
Prior art keywords
knock
mouse models
glutaminyl cyclase
out mutation
cyclase gene
Prior art date
Application number
IL206484A
Other languages
English (en)
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of IL206484A0 publication Critical patent/IL206484A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
IL206484A 2008-01-14 2010-06-20 Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene IL206484A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2078408P 2008-01-14 2008-01-14
PCT/EP2009/050387 WO2009090190A1 (en) 2008-01-14 2009-01-14 Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene

Publications (1)

Publication Number Publication Date
IL206484A0 true IL206484A0 (en) 2010-12-30

Family

ID=40427980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL206484A IL206484A0 (en) 2008-01-14 2010-06-20 Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene

Country Status (9)

Country Link
US (1) US9462793B2 (https=)
EP (1) EP2238252B1 (https=)
JP (1) JP2011511622A (https=)
AU (1) AU2009204864A1 (https=)
CA (1) CA2710494A1 (https=)
IL (1) IL206484A0 (https=)
NZ (1) NZ586665A (https=)
WO (1) WO2009090190A1 (https=)
ZA (1) ZA201004367B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174987B1 (en) 2014-08-01 2023-10-11 The Johns Hopkins University Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US20030013177A1 (en) * 2001-05-23 2003-01-16 Ebens Allen J. Polynucleotides encoding insect glutaminyl cyclase and uses thereof
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
KR20110059664A (ko) 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
JP5690463B2 (ja) 2003-05-05 2015-03-25 プロビオドルグ エージー グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
BRPI0718507A2 (pt) 2006-09-21 2013-11-12 Probiodrug Ag Genes relacionados à glutaminil ciclase
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US8420684B2 (en) 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP2010516235A (ja) * 2007-01-19 2010-05-20 プロビオドルグ エージー アルツハイマー病及び他のｑｐｃｔ関連障害の治療のためのインビボスクリーニングモデル
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
DK2142515T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer
JP5675343B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5675340B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー 新規阻害剤
WO2008128983A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
CA2696934A1 (en) 2007-09-12 2010-02-16 Probiodrug Ag Transgenic mice

Also Published As

Publication number Publication date
EP2238252B1 (en) 2013-07-31
WO2009090190A9 (en) 2010-08-26
EP2238252A1 (en) 2010-10-13
NZ586665A (en) 2011-12-22
ZA201004367B (en) 2011-08-31
US9462793B2 (en) 2016-10-11
JP2011511622A (ja) 2011-04-14
WO2009090190A1 (en) 2009-07-23
US20090183267A1 (en) 2009-07-16
AU2009204864A1 (en) 2009-07-23
CA2710494A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
IL214820A0 (en) Novel genes related to glutaminyl cyclase
GB0908913D0 (en) Software development tool
EP2359304A4 (en) Forming a model of a subsurface region
GB0800263D0 (en) A method of creating a representation of the surface of an object
GB0800797D0 (en) Neural interface
EP2443545A4 (en) COMPUTER-USER SURFACE INTERACTION
ZA201006705B (en) Method for the production of a highly abrasion-resistant vehicle paint,vehicle paint,and the use thereof
GB2497042B (en) Graphical user interface for music sequence programing
GB0719625D0 (en) Improved method of creating a computer model of the physical world
GB0813343D0 (en) A sound creation interface
EP2480965A4 (en) COMPUTER MODEL OF MULTI-LEVEL EVENTS
EP2561438A4 (en) UPDATE A USER INTERFACE
EP2052299A4 (en) INTERACTIVE MUSIC INTERFACE FOR COMPOSING MUSIC
GB2495247B (en) Well tool having a nanoparticle reinforced metallic coating
HUE040100T2 (hu) Futtatható konfiguráció elõállítása
GB0908780D0 (en) A nano-scale manipulator
ZA201004367B (en) Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
ZA201100916B (en) A laptop computer
IL216082A0 (en) Mouse models carrying a knock-out mutation of the qpctl-gene
HK1149586A (en) Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
ZA200901123B (en) Novel genes related to glutaminyl cyclase
GB0800574D0 (en) Mouse models carrying a knock-out mutation of the QPCT-gene
GB0908608D0 (en) Mouse models carrying a knock-out mutation of the QPCTL-gene
HK1167070A (en) Mouse models carrying a knock-out mutation of the qpctl-gene
GB0819747D0 (en) Computer mouse and program